The amyloid-β Pathway in Alzheimer’s Disease: A Plain Language Summary
Neurodegenerative Disease Management · 2023
DOI: 10.2217/nmt-2022-0037 ↗Kurz gefasst
Kommentar in der Zeitschrift Neurodegenerative Disease Management, 2023. Verfasst von Harald Hampel und 15 weiteren Autor:innen. Beteiligte Einrichtung: Eisai Inc., Alzheimer's Disease & Brain Health, Nutley, NJ, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloidosis. Die Arbeit wurde bisher 44-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
WHAT IS THIS SUMMARY ABOUT?: This plain language summary of an article published in Molecular Psychiatry, reviews the evidence supporting the role of the amyloid-β (Aβ) pathway and its dysregulation in Alzheimer's disease (AD), and highlights the rationale for drugs targeting the Aβ pathway in the early stages of the disease. WHY IS THIS IMPORTANT?: Aβ is a protein fragment (or peptide) that exists in several forms distinguished by their size, shape/structure, degree of solubility and disease relevance. The accumulation of Aβ plaques is a hallmark of AD. However, smaller, soluble aggregates of Aβ - including Aβ protofibrils - also play a role in the disease. Because Aβ-related disease mechanisms are complex, the diagnosis, treatment and management of AD should be reflective of and guided by up-to-date scientific knowledge and research findings in this area. This article describes the Aβ protein and its role in AD, summarizing the evidence showing that altered Aβ clearance from the brain may lead to the imbalance, toxic buildup and misfolding of the protein - triggering a cascade of cellular, molecular and systematic events that ultimately lead to AD. WHAT ARE THE KEY TAKEAWAYS?: The physiological balance of brain Aβ levels in the context of AD is complex. Despite many unanswered questions, mounting evidence indicates that Aβ has a central role in driving AD progression. A better understanding of the Aβ pathway biology will help identify the best therapeutic targets for AD and inform treatment approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eisai Inc., Alzheimer's Disease & Brain Health, Nutley, NJ, USA.
- UK Dementia Research Institute at UCL & Department of Neurodegenerative Disease, UCL Institute of Neurology, University College London, London, UK.
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
- Institute of Neuroscience & Physiology, Department of Psychiatry & Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
- Memory Aging & Cognition Centre, Departments of Pharmacology & Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Department of Biology & Neurosciences Institute, University of Texas at San Antonio, San Antonio, TX, USA.
Förderung
- NIGMS NIH HHS
- NIA NIH HHS
Zitieren
APA
Hampel, H., Hu, Y., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., Masters, C. L., Cho, M., Lannfelt, L., Cummings, J. L., & Vergallo, A. (2023). The amyloid-β Pathway in Alzheimer’s Disease: A Plain Language Summary. Neurodegenerative Disease Management. https://doi.org/10.2217/nmt-2022-0037
Vancouver
Hampel H, Hu Y, Hardy J, Blennow K, Chen C, Perry G, et al. The amyloid-β Pathway in Alzheimer’s Disease: A Plain Language Summary. Neurodegenerative Disease Management. 2023. doi:10.2217/nmt-2022-0037
BibTeX
@article{Hampel2023,
author = {Hampel, Harald and Hu, Yan and Hardy, John and Blennow, Kaj and Chen, Christopher and Perry, George and Kim, Seung Hyun and Villemagne, Victor L and Aisen, Paul and Vendruscolo, Michele and Iwatsubo, Takeshi and Masters, Colin L and Cho, Min and Lannfelt, Lars and Cummings, Jeffrey L and Vergallo, Andrea},
title = {The amyloid-β Pathway in Alzheimer’s Disease: A Plain Language Summary},
journal = {Neurodegenerative Disease Management},
year = {2023},
doi = {10.2217/nmt-2022-0037}
}
EUVIMED